BRÈVE

sur ABIVAX (EPA:ABVX)

Abivax Announces Availability of Documents for Upcoming General Meeting

Abivax SA, a clinical-stage biotechnology company listed on Euronext Paris and Nasdaq, has officially announced that its upcoming ordinary and extraordinary general meeting is scheduled for May 30, 2024, at 10:00 am CEST. The meeting will take place at the Dechert (Paris) LLP offices on rue Bayard, Paris. Ahead of the general meeting, the company has made all crucial preparatory documents available for shareholder review.

The essential documents, including the preliminary notice of the meeting with the agenda and draft resolutions, have been published in the Bulletin des Annonces Légales Obligatoires on April 24, 2024. Shareholders wishing to obtain these materials via postal or electronic means can request until May 25, 2024. Additionally, bearer shareholders are required to provide a registration certificate from their securities account.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de ABIVAX